<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344483</url>
  </required_header>
  <id_info>
    <org_study_id>1506</org_study_id>
    <nct_id>NCT04344483</nct_id>
  </id_info>
  <brief_title>Effect of Lidocaine and Adrenaline Soaked Gauze Versus Normal Saline Soaked at Skin Graft Donor Site of Thigh</brief_title>
  <official_title>Effect of Lidocaine and Adrenaline Soaked Gauze Versus Normal Saline Soaked at Skin Graft Donor Site of Thigh: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      I am studying the effects of Lidocaine and Adrenaline Soaked Gauze vs Normal Saline Soaked
      Gauze at Skin Graft Donor Site of Thigh.

      Haemostatic effect, epithelization and post operative pain will be assessed on follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After admission of the patients, they will be randomized either to be in Group A or Group B.
      Closed envelop technique will be used for random assignment of the patients.

      Group A will be receiving 2% lidocaine and 1:100,000 adrenaline soaked gauze while group B
      will be given only normal saline soaked gauze at donor-site for ten minutes.

      The primary end point of study is intraoperative bleeding. The secondary end points of study
      include no. of hydrocolloid dressings remained on donor-site, epithelization at donor site on
      14th post-operative day, post-operative pain immediately after surgery and graft viability.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients with non healing wound who will otherwise be healthy will be recruited in the study and will randomly assign groups. One group will receive Adrenaline and Lidocaine soaked gauze and the second group will be a control group who will receive normal saline soaked gauze.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be recruited in the study by closed envelope technique and the study will be single blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intra operatieve bleeding</measure>
    <time_frame>per operative</time_frame>
    <description>Intra-operative Bleeding from donor site of graft will be assessed per operatively as being normal or more than normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative bleeding</measure>
    <time_frame>24 hours</time_frame>
    <description>post operative bleeding will be assesd in post operative period by number of dressings required.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>24 hours</time_frame>
    <description>post operative pain will be assesd in the post operative period by visual analog score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesia requirement</measure>
    <time_frame>24 hours</time_frame>
    <description>Post operative analgesia requirement of patient will be observed by number of medications required</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epithelization of donor site</measure>
    <time_frame>14 days</time_frame>
    <description>Epithelization over donor site will be assessed on 14th post operative day by subjective assesment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-healing Wound</condition>
  <arm_group>
    <arm_group_label>Group A ( Lidocaine + Adrenaline)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and hydrocolloid dressing will be applied over donor site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B ( Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and hydrocolloid dressing will be applied over donor site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% Lidocaine and 1:100,000 Adrenaline</intervention_name>
    <description>Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.</description>
    <arm_group_label>Group A ( Lidocaine + Adrenaline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.</description>
    <arm_group_label>Group B ( Normal Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patients of both the gender of age &gt; 15 years

               -  Multiple donor-sites

        Exclusion Criteria:

        Bleeding disorder

          -  Concomitant injuries

          -  Donor site other than thigh

          -  Previously harvested donor-site

          -  Patients on antiplatelet medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zaara Zahid, MBBS</last_name>
    <phone>03343501804</phone>
    <email>zaarazahid@hotmail.com</email>
  </overall_contact>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/18950945</url>
    <description>Gacto P, Miralles F, Pereyra J, Perez A, Martinez E. Haemostatic effects of adrenaline-lidocaine subcutaneous infiltration at donor sites. Burns. 2009;35(3):343-7.</description>
  </link>
  <results_reference>
    <citation>Gacto P, Miralles F, Pereyra JJ, Perez A, Martínez E. Haemostatic effects of adrenaline-lidocaine subcutaneous infiltration at donor sites. Burns. 2009 May;35(3):343-7. doi: 10.1016/j.burns.2008.06.019. Epub 2008 Oct 23.</citation>
    <PMID>18950945</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Zaara Zahid</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

